Stromelysin-3: A paradigm for stroma-derived factors implicated in carcinoma progression

Critical Reviews in Oncology/Hematology

Volumn 26, Issue 1, 1997, Pages 43-53

  Basset, Paul ^a,c   Bellocq, Jean Pierre ^b,c   Lefebvre, Olivier ^a,d   Noël, Agnès ^a,e   Chenard, Marie Pierre ^b,c   Wolf, Catherine ^a,f   Anglard, Patrick ^a,d   Rio, Marie Christine ^a,d  

^a INSTITUT DE GÉNÉTIQUE ET DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

^b HÔPITAL DE HAUTEPIERRE   (France)

^c Faculté de Médecine of Strasbourg   (France)

^d INSERM   (France)

^e Fond National de la Recherche Scientifique of Belgium   (Belgium)

^f Technical Affairs   (France)

Author keywords

[No Author keywords available]

Indexed keywords

MATRIX METALLOPROTEINASE; STROMELYSIN;

CARCINOMA; EXTRACELLULAR MATRIX; GENE EXPRESSION; HUMAN; REVIEW; STROMA;

EID: 0030839724     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(97)00010-3     Document Type: Article

References (99)

1. Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 1986;315:1650-9.
2. Van den Hoof A. Stromal involvement in malignant growth. Adv Cancer Res 1988;50:159-96.
3. Van Scott EJ, Reinerston RP. The modulating influence of stromal environment on epithelial cells studied in human autotransplants. J Invest Dermatol 1961;36:109-31.
4. Sakakura T, Sakagami Y, Nishizuka Y. Accelerated mammary cancer development by fetal salivary mesenchyma isografted to adult mouse mammary epithelium. J Natl Cancer Inst 1981;66:953-9.
5. Cunha GR, Hom YK. Role of mesenchymal-epithelial interactions in mammary gland development. J Mammary Gland Biol Neoplasia 1996;1:21-35.
6. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353-64.
7. Zipori D. Stromal cells in tumor growth and regression. Cancer J 1990;3:164-9.
8. Basset P, Bellocq JP, Wolf C, et al. A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas. Nature 1990;348:699-704.
9. Pyke C, Kristensen P, Ralfkiaer E, et al. Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. Am J Pathol 1991;138:1059-67.
10. MacDougall JR, Matrisian LM. Contributions of tumor and stromal matrix metalloproteinases to tumor progression, invasion and metastasis. Cancer Metast Rev 1995;14:351-62.
11. Mignatti P, Rifkin DB. Biology and biochemistry of proteinases in tumor invasion. Physiol Rev 1993;73:161-95.
12. Duffy MJ. Proteases as prognostic markers in cancer. Clin Cancer Res 1996;2:613-8.
13. Stetler-Stevenson WG, Hewitt R, Corcoran M. Matrix metalloproteinases and tumor invasion: From correlation and causality to the clinic. Cancer Biol 1996;7:147-54.
14. Liotta LA. Cancer cell invasion and metastasis. Sci Am 1992;266(2):34-41.
15. Coussens LM, Werb Z. Matrix metalloproteinases and the development of cancer. Chem Biol 1996;15:535-41.
16. Basset P, Okada A, Chenard MP, et al. Matrix metalloproteinases as stromal effectors of human carcinoma progression: Therapeutical implications. Matrix Biol 1997;15:535-41.
17. Matrisian LM. Metalloproteinases and their inhibitors in matrix remodeling. Trends Genet 1990;6:121-5.
18. Stöcker W, Bode W. Structural features of a superfamily of zinc-endopeptidases: The metzincins. Curr Opin Struct Biol 1995;5:383-90.
19. Lefebvre O, Wolf C, Limacher JM, et al. The breast cancer-associated stromelysin-3 gene is expressed during mouse mammary gland apotosis. J Cell Biol 1992;119:997-1002.
20. Okada A, Saez S, Misumi Y, Basset P. Rat stromelysin 3: cDNA cloning from healing skin wound, activation by furin and expression in rat tissues. Gene 1997;185:187-93.
21. Patterton D, Hayes WP, Shi YB. Transcriptional activation of the matrix metalloproteinase gene stromelysin-3 coincides with thyroid hormone-induced cell death during frog metamorphosis. Dev Biol 1995;167:252-62.
22. Birkedal-Hansen H. Proteolytic remodeling of extracellular matrix. Curr Opin Cell Biol 1995;7:728-35.
23. Murphy GJP, Murphy G, Reynolds JJ. The origin of matrix metalloproteinases and their familial relationships. FEBS Lett 1991;289:4-7.
24. Levy A, Zucman J, Delattre O, Mattei MG, Rio MC, Basset P. Assignment of the human stromelysin-3 (STMY3) gene to the q11.2 region of chromosome 22. Genomics 1992;13:881-3.
25. De Souza SJ, Brentani R. Sequence homology between a bacterial metalloproteinase and eukaryotic matrix metalloproteinases. J Mol Evol 1993;36:596-8.
26. Woessner JF. The family of matrix metalloproteinases. Ann NY Acad Sci 1994;732:11-21.
27. Takahashi S, Hatsuzawa K, Watanabe T, Murakami K, Nakayama K. Sequence requirements for endoproteolytic processing of precursor proteins by furin: Transfection and in vitro experiments. J Biochem 1994;116:47-52.
28. Pei D, Weiss SJ. Furin-dependent intracellular activation of the human stromelysin-3 zymogen. Nature 1995;375:244-7.
29. Santavicca M, Noël A, Angliker H, et al. Characterization of structural determinants and molecular mechanisms involved in pro-stromelysin-3 activation by 4-aminophenylmercuric acetate and furin-type convertases. Biochem J 1996;315:953-8.
30. Murphy G, Segain JP, O'Shea M, et al. The 28 kDa N-terminal domain of mouse stromelysin-3 has the general properties of a weak metalloproteinase. J Biol Chem 1993;268:15435-41.
31. Pei D, Majmudar G, Weiss SJ. Hydrolytic inactivation of a breast carcinoma cell-derived serpin by human stromelysin-3. J Biol Chem 1994;269:25849-55.
32. Noël A, Santavicca M, Stoll I, et al. Identification of structural determinants controlling human and mouse stromelysin-3 proteolytic activities. J Biol Chem 1995;270:22866-72.
33. 1-antitrypsin. Biochem Biophys Res Commun 1994;204:613-20.
34. Zhang Z, Winyard PG, Chidwick K, et al. Proteolysis of human native and oxidised alpha 1-proteinase inhibitor by matrilysin and stromelysin. Biochim Biophys Acta 1994;1199:224-8.
35. Rawlings ND, Barrett AJ. Evolutionary families of metallopeptidases. Methods Enzymol 1995;248:183-228.
36. Urbanski SJ, Edwards DR, Maitland A, Leco KJ, Watson A, Kossakowska AE. Expression of metalloproteinases and their inhibitors in primary pulmonary carcinomas. Br J Cancer 1992;66:1188-94.
37. Wagner SN, Ruhri C, Kunth K, et al. Expression of stromelysin 3 in the stromal elements of human basal cell carcinoma. Diagn Mol Pathol 1992;3:200-5.
38. Wolf C, Chenard MP, Durand de Grossouvre P, Bellocq JP, Chambon P, Basset P. The breast cancer-associated stromelysin-3 gene is expressed in basal cell carcinoma and during cutaneous wound healing. J Invest Dermatol 1992;99:870-2.
39. Muller D, Wolf C, Abecassis J, et al. Increased stromelysin-3 gene expression is associated with increased local invasiveness in head and neck squamous cell carcinomas. Cancer Res 1993;53:165-9.
40. Wolf C, Rouyer N, Lutz Y, et al. Stromelysin-3 belongs to a subgroup of proteinases expressed in breast carcinoma fibroblastic cells and possibly implicated in tumor progression. Proc Natl Acad Sci USA 1993;90:1843-7.
41. Hähnel E, Harvey JM, Joyce R, Robbins PD, Sterrett GF, Hähnel R. Stromelysin-3 expression in breast cancer biopsies: clinico-pathological correlations. Int J Cancer 1993;55:771-4.
42. Kawami H, Yoshida K, Ohsaki A, Kuroi K, Nishiyama M, Toge T. Stromelysin-3 mRNA expression and malignancy: Comparison with clinicopathological features and type IV collagenase mRNA expression in breast tumors. Anticancer Res 1993;13:2319-24.
43. Polette M, Clavel C, Birembaut P, De Clerek YA. Localization by in situ hybridization of mRNAs encoding stromelysin 3 and tissue inhibitors of metallo-proteinases TIMP-1 and TIMP-2 in human head and neck carcinomas. Pathol Res Pract 1993;189:1052-7.
44. Bellocq JP, Chenard-Neu MP, Rouyer N, Wolf C, Chambon P, Basset P. Stromelysin-3 gene expression in breast and other human carcinomas. In: Schmitt M, Graeff H, Kindermann G, editors. Prospects in Diagnosis and Treatment of Breast Cancer. Munich: Elsevier, 1993:187-197.
45. Urbanski SJ, Edwards DR, Hershfield N, et al. Expression pattern of metalloproteinases and their inhibitors changes with the progression of human sporadic colorectal neoplasia. Diagn Mol Pathol 1993;2:81-9.
46. Majmudar G, Nelson BR, Jensen TC, Voorhees JJ, Johnson TM. Increased expression of stromelysin-3 in basal cell carcinomas. Mol Carcinogen 1994;9:17-23.
47. Engel G, Heseemeyer K, Auer G, Backdahl M, Eriksson E, Linder S. Correlation between stromelysin-3 mRNA level and outcome of human breast cancer. Int J Cancer 1994;58:830-5.
48. Rouyer N, Wolf C, Chenard MP, et al. Stromelysin-3 gene expression in human cancer: An overview. Invas Metast 1994;14:269-75.
49. Porte H, Chastre E, Prevot S, et al. Neoplastic progression of human colorectal cancer is associated with overexpression of the stromelysin-3 and BM-40 SPARC genes. Int J Cancer 1995;64:70-5.
50. Anderson IC, Sugarbaker DJ, Ganju RK, et al. Stromelysin-3 is overexpressed by stromal elements in primary non-small cell lung cancers and regulated by retinoic acid in pulmonary fibroblasts. Cancer Res 1995;55:4120-6.
51. Heppner KJ, Matrisian LM, Jensen RA, Rodgers WH. Expression of most matrix metalloproteinase family members in breast cancer represents a tumor-induced host response. Am J Pathol 1996;149:273-82.
52. Linden AB, Sandstedt B, Bruce KL, Hedblad MA, Stahle-Bäckdahl M. Stromelysin-3 mRNA associated with myofibroblasts is overexpressed in aggressive basal cell carcinoma and in dermatofibroma but not in dermatofibrosarcoma. J Invest Dermatol 1996;107:147-53.
53. Johnson LD, Hunt DM, Kim K, Nachtigal M. Amplification of stromelysin-3 transcripts from carcinomas of the colon. Hum Pathol 1996;27:964-8.
54. Chenard MP, O'Siorain L, Shering S, et al. High levels of stromelysin-3 correlate with poor prognosis in patients with breast carcinoma. Int J Cancer 1996;69:448-51.
55. Grégoire M, Lieubeau B. The role of fibroblasts in tumor behavior. Cancer Metast Rev 1995;14:339-50.
56. Lane TE, Sage EH. The biology of SPARC, a protein that modulates cell-matrix interactions. FASEB J 1994;8:163-73.
57. Podhajcer OL, Wolf C, Lefebvre O, et al. Comparative expression of the SPARC and stromelysin-3 genes in mammary tumours. The Breast 1996;5:13-20.
58. Rodgers WH, Matrisian LM, Giudice LC, et al. Patterns of matrix metalloproteinase expression in cycling endometrium imply differential functions and regulation by steroid hormones. J Clin Invest 1994;94:946-53.
59. Lefebvre O, Régnier C, Chenard MP, et al. Developmental expression of mouse stromelysin-3 mRNA. Development 1995;121:947-55.
60. Okada, A., Tomasetto, C., Lutz, Y., Bellocq, J.P., Rio, M.C., Basset, P., Expression of matrix metalloproteinases during rat skin wound healing: Evidence that membrane-type-1 matrix metalloprotemase (MT1-MMP) is a stromal activator of progelatinase A. J Cell Biol 1997 (in press).
61. Maquoi, E., Polette, M., Nawrocki, M. et al., Expression of stromelysin-3 in the human placenta and placental bed. Placenta 1997 (in press).
62. Hähnel E, Dwakins H, Robbins P, Hähnel R. Expression of stromelysin-3 and nm23 in breast carcinoma and related tissues. Int J Cancer 1994;58:157-60.
63. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis-Correlation in invasive breast carcinoma. N Engl J Med 1991;324:1-8.
64. Rak J, Filmus J, Finkenzeller G, Grugel S, Marmé D, Kerbel RS. Oncogenes as inducers of tumor angiogenesis. Cancer Metast Rev 1995;14:263-77.
65. Okada A, Bellocq JP, Rouyer N, et al. Membrane-type matrix metalloproteinase (MT-MMP) gene is expressed in stromal cells of human colon, breast, and head and neck carcinomas. Proc Natl Acad Sci USA 1995;92:2730-4.
66. Anglard P, Melot T, Guérin E, Thomas G, Basset P. Structure and promoter characterization of the human stromelysin-3 gene. J Biol Chem 1995;270:20337-44.
67. Guérin, E., Ludwig, M.G., Basset, P., Anglard, P., Stromelysin-3 induction and interstitial collagenase repression by retinoic acid: Therapeutical implication of receptor-selective retinoids dissociating transactivation and AP-1 mediated-transrepression. J Biol Chem 1997 (in press).
68. Gaire M, Magbanua Z, McDonnell S, McNeil L, Lovett DH, Matrisian LM. Structure and expression of the human gene for the matrix metalloproteinase matrilysin. J Biol Chem 1994;269:2032-40.
69. Lafyatis R, Kim SJ, Angel P, et al. Interleukin-1 stimulates and all-trans-retinoic acid inhibits collagenase gene expression through its 5′ activator binding site. Mol Endocrinol 1990;4:973-80.
70. Nicholson RC, Mader S, Nagpal S, Leid M, Rochette-Egly C, Chambon P. Negative regulation of the rat stromelysin gene promoter by retinoic acid is mediated by an API binding site. EMBO J 1990;9:4443-54.
71. Noël A, Lefebvre O, Maquoi E, et al. Stromelysin-3 expression promotes tumor take in nude mice. J Clin Invest 1996;97:1924-30.
72. Witty JP, McDonnell S, Newell KJ, et al. Modulation of matrilysin levels in colon carcinoma cell lines affects tumorigenicity in vivo. Cancer Res 1994;54:4805-12.
73. Fowlkes JL, Enghild JJ, Suzuki K, Nagase H. Matrix metalloproteinases degrade insulin-like growth factor-binding protein-3 in dermal fibroblast cultures. J Biol Chem 1994;269:25742-6.
74. Levi E, Fridman R, Miao HQ, Ma YS, Yayon A, Vlodavsky I. Matrix metalloproteinase 2 releases active solube ectodomain of fibroblast growth factor receptor 1. Proc Natl Acad Sci USA 1996;93:7069-74.
75. Broder S. The challenge of cancer research. Stem Cells 1993;11:3-8.
76. Lippman ME. The development of biological therapies for breast cancer. Science 1993;259:631-2.
77. Brown PD. Matrix metalloproteinase inhibitors: a new class of anticancer agent. Curr Opin Invest Drugs 1993;2:617-26.
78. Davies B, Brown PD, East N, Crimmin MJ, Balkwill FR. A synthetical matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts. Cancer Res 1993;53:2087-91.
79. Chirivi RGS, Garofalo A, Crimmin MJ, et al. Inhibition of the metastatic spread and growth of B16-BL6 murine melanoma by a synthetic matrix metalloproteinase inhibitor. Int J Cancer 1994;58:460-4.
80. Naito K, Kanbayashi M, Makajima S, et al. Inhibition of growth of human tumor cells in nude mice by a metalloproteinase inhibitor. Int J Cancer 1994;58:730-5.
81. Wang X, Fu X, Brown PD, Crimmin MJ, Hoffman RM. Matrix metalloproteinase inhibitor BB-94 (Batimastat) inhibits human colon tumor growth and spread in a patient-like orthotopic model in nude mice. Cancer Res 1994;54:4726-8.
82. Eccles SA, Box GM, Court WJ, Bone EA, Thomas W, Brown PD. Control of lymphatic and hematogenous metastasis of a rat mammary carcinoma by the matrix metalloproteinase inhibitor batimastat (BB-94). Cancer Res 1996;56:2815-22.
83. Low JA, Johnson MD, Bone EA, Dickson RB. The matrix metalloproteinase inhibitor batimastat (BB-94) retards human breast cancer solid tumor growth but not ascites formation in nude mice. Clin Cancer Res 1996;2:1207-14.
84. Brown PD, Giavazzi R. Matrix metalloproteinase inhibition: A review of anti-tumour activity. Ann Oncol 1995;6:967-74.
85. Beckett RP. Recent advances in the field of matrix metalloproteinase inhibitors. Exp Opin Ther Patents 1996;6:1305-15.
86. Blundell TL. Metalloproteinase super-families and drug design. Nature Struct Biol 1994;1:73-5.
87. Hodgson J. Remodeling MMPIs. Bio Technology 1995;13:554-7.
88. Stolow MA, Bauzon DD, Li J, et al. Identification and characterization of a novel collagenase in Xenopus laevis: Possible roles during frog development. Mol Biol Cell 1996;7:1471-83.
89. Cossins J, Dudgeon TJ, Catlin G, Gearing AJH, Clements JM. Identification of MMP-18, a putative novel human matrix metalloproteinase. Biochem Biophys Res Commun 1996;228:494-8.
90. Pendas AM, Knauper V, Puente XS, et al. Identification and characterization of a novel matrix metalloproteinase with unique structural characteristics, chromosomal localization, and tissue distribution. J Biol Chem 1997;272:4281-6.
91. Sedlacek, R., Mauch, S., Kolb, B. et al., The novel matrix metalloproteinase RASI-1 is expressed on the surface of activated peripheral blood mononuclear cells and is detected as an autoantigen in rheumatoid arthritis. J Clin Invest 1997 (in press).
92. Bartlett JD, Simmer JP, Xue J, Margolis HC, Moreno EC. Molecular cloning and mRNA tissue distribution of a novel matrix metalloproteinase isolated from porcine enamel organ. Gene 1996;183:123-8.
93. Takino T, Sato H, Shinagawa A, Seiki M. Identification of the second membrane-type matrix metalloproteinase (MT-MMP-2) gene from a human placenta cDNA library. J Biol Chem 1995;270:23013-20.
94. Will H, Hinzmann B. cDNA sequence and mRNA tissue distribution of a novel human matrix metalloproteinase with a potential transmembrane segment. Eur J Biochem 1995;231:602-8.
95. 1′ pocket mutations in matrilysin and stromelysin-1. Biochemistry 1996;35:10103-9.
96. Reinemer P, Grams F, Huber R, et al. Structural implications for the role of the N terminus in the superactivation of collagenases. A crystallographic study. FEBS Lett 1994;338:227-33.
97. Bode W, Gomis-Rüth FX, Stöcker W. Astacins, serralysins, snake venom and matrix metalloproteinases exhibit identical zinc-binding environments (HEXXHXXGXXH and Met-turn) and topologies and should be grouped into a common family, the 'metzincins', FEBS Lett 1993;331:134-40.
98. Mouriquand J, Mouriquand C, Viala C. Activité biologique des différentes zones obtenues par ultracentrifugation du facteur lacté de la souche de souris PS sur gradients préformés de ficoll. Eur J Cancer 1970;6:115-24.
99. Andres AC, van der Valk MA, Schönenberger CA, et al. Ha-ras and c-myc oncogcne expression interferes with morphological and functional differentiation of mammary epithelial cells in single and double transgenic mice. Genes Dev 1988;2:1486-95.